Trevi Therapeutics Inc
General ticker "TRVI" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $326.9M
Trevi Therapeutics Inc follows the US Stock Market performance with the rate: 44.0%.
Estimated limits based on current volatility of 7.6%: low 4.00$, high 4.47$
Factors to consider:
- Current price 95.9% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.70$, 2.07$]
- 2024-12-30 to 2025-12-30 estimated range: [0.74$, 2.11$]
Financial Metrics affecting the TRVI estimates:
- Negative: Non-GAAP EPS, $ of -0.29 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -20.97 <= 2.35
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0 <= 0.14
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TRVI quotes
Long-term TRVI plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.48MM | $29.91MM | $33.92MM |
| Operating Income | $-32.48MM | $-29.91MM | $-33.92MM |
| Non-Operating Income | $-1.49MM | $0.72MM | $4.83MM |
| Interest Expense | $1.20MM | $0.78MM | $0.39MM |
| R&D Expense | $22.98MM | $19.83MM | $23.68MM |
| Income(Loss) | $-33.96MM | $-29.19MM | $-29.10MM |
| Taxes | $-0.02MM | $-0.04MM | $-0.03MM |
| Profit(Loss) | $-33.94MM | $-29.15MM | $-29.07MM |
| Stockholders Equity | $17.07MM | $107.46MM | $82.55MM |
| Assets | $38.48MM | $123.02MM | $89.40MM |
| Operating Cash Flow | $-28.95MM | $-28.18MM | $-31.71MM |
| Capital expenditure | $0.00MM | $0.16MM | $0.14MM |
| Investing Cash Flow | $0.00MM | $-107.37MM | $59.43MM |
| Financing Cash Flow | $20.77MM | $111.31MM | $-7.91MM |
| Earnings Per Share* | $-1.49 | $-0.45 | $-0.29 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.